MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS), a biotech firm focused on developing novel treatments for neurodegenerative diseases, announced the successful completion of data cleaning for its pivotal phase II/III study of buntanetap in patients with mild to moderate Alzheimer’s disease. The company expects to release topline efficacy data in April, marking a significant step forward in the quest for effective Alzheimer’s treatments.
The study in question was a rigorous, randomized, double-blind, placebo-controlled trial designed to assess the efficacy, safety, and tolerability of buntanetap, a therapeutic candidate that has generated considerable interest within the medical community. Over the course of 12 weeks, patients received one of three doses of buntanetap—7.5mg, 15mg, or 30mg—or a placebo, in addition to their standard care. Out of more than 700 patients screened, 353 were enrolled, with 327 completing the study—a testament to the dedication of participants, caregivers, and the research team.
Cheng Fang, Ph.D., Senior Vice President of Annovis, expressed enthusiasm about the progress, stating, “To clean data this fast is truly a tremendous achievement. The team has been working hard to provide trustworthy data, and we look forward to sharing the topline results next month.” Data cleaning, a critical process in clinical trials, involves checking for and correcting inaccuracies or inconsistencies to ensure the data’s reliability for analysis.
Melissa Gaines, Senior Vice President of Clinical Operations at Annovis, also highlighted the vital role of participants and study partners in reaching this milestone. “We are grateful to the participants, their caregivers and families, and our study partners whose teamwork and dedication allowed us to complete the study in a timely fashion,” she said.
As the healthcare community eagerly awaits the topline results, this announcement from Annovis Bio emphasizes the ongoing efforts to combat Alzheimer’s disease, a condition that affects millions worldwide. With the completion of the data cleaning phase, Annovis Bio moves closer to potentially providing a new therapeutic option for patients with mild to moderate Alzheimer’s disease, offering hope for improved treatments in the near future.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.